Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 12/20 | 0.52 |
| ▸ | PPARG | P37231 | 10/20 | 0.52 |
| ▸ | PPARD | Q03181 | 5/20 | 0.52 |
| ▸ | SRR | Q9GZT4 | 4/20 | 0.47 |
| ▸ | PSAT1 | Q9Y617 | 2/20 | 0.46 |
| ▸ | CSK | P41240 | 1/20 | 0.46 |
| ▸ | LDHA | P00338 | 1/20 | 0.45 |
| ▸ | LPL | P06858 | 1/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4263574 | 0.81 | PPARG (0.48) | PPARAPPARGPPARDSRRLPL | |
| SCHEMBL4451311 | 0.81 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL4941128 | 0.81 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL3466702 | 0.81 | PPARA (0.56) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL16877217 | 0.80 | SRR (0.70) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL2517934 | 0.80 | SRR (0.70) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL9628212 | 0.80 | SRR (0.70) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL24328239 | 0.79 | PPARG (0.59) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL5606722 | 0.79 | PPARA (0.55) | PPARAPPARGPPARDSRRPSAT1 | |
| SCHEMBL4811729 | 0.79 | PPARA (0.55) | PPARAPPARGPPARDSRRPSAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048258-A1 | Amide Compound | TAKEDA, PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| EP-1845081-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048258-A1 | Amide Compound | DLAT, DGAT1, DGAT2 | PPARA 323/4885PPARG 80/4885PPARD 924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.